BCLI
BRAINSTORM CELL THERAPEUTICS INC.Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2025: 1 added (0 new), 1 trimmed or exited.
- EstimatesRISING
Current-quarter EPS estimate −$0.210 → −$0.180 over 90 days. 1 up, 0 down in 30 days.
- TrendDOWNTREND
18% below its 50-day average.
Who's buying
13F· Q2 2025| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $13.9K |
| FMR LLC | NEAR_EXIT | $7.00 |
| UBS Group AG | NEAR_EXIT | $319.00 |
| FMR LLC | DOUBLED | $294.00 |
| JPMORGAN CHASE & CO | DOUBLED | $215.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Jul 2024| Date | Firm | Rating |
|---|---|---|
| Jul 11, 2024 | Maxim Group UPGRADE | Buy |
| Sep 28, 2023 | Maxim Group DOWNGRADE | Hold |
| Mar 31, 2023 | Maxim Group MAINTAIN | Buy |
| Feb 5, 2021 | Maxim Group UPGRADE | Buy |
| May 15, 2018 | HC Wainwright & Co. INITIATE | Buy |
| Aug 17, 2017 | Maxim Group MAINTAIN | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jul 24, 2026 | Pitts Peter Joe Executive Chairman | AWARD | 900,000 sh |
| Jul 24, 2026 | FRENKEL JACOB A Director | AWARD | 100,000 sh |
| Feb 26, 2026 | Bairu Menghisteab Director | AWARD | $105.0K |
| Feb 26, 2026 | Lebovits Chaim President & CEO | AWARD | 1,800,000 sh |
| Feb 26, 2026 | Polverino Anthony J. Director | AWARD | $105.0K |
| Feb 26, 2026 | Dagher Ibrahim B. Director | AWARD | $157.5K |
| Feb 26, 2026 | Lindborg Stacy Director | AWARD | $105.0K |
| Feb 26, 2026 | Patlis Alla See Remarks | AWARD | 100,000 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.18 | -$0.18–-$0.18 | — | $0.00 |
| Next Q | -$0.19 | -$0.19–-$0.19 | — | $0.00 |
| Current FY | -$0.91 | -$0.91–-$0.91 | — | $0.00 |
| Next FY | -$1.02 | -$1.02–-$1.02 | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
4 filings · 1 bullish · 2 bearish · 1 neutral- BEARISH EFFECTJun 3, 2026
BrainStorm Cell Therapeutics' S-1 registration statement (File No. 333-296090) was declared…
The shelf registration is now effective, meaning BrainStorm can sell shares at any time, creating an overhang of potential dilution. Monitor for a prospectus supplement or 8-K announcing a specific…
- NEUTRAL 8-KMay 28, 2026
Brainstorm Cell Therapeutics appointed former FDA Associate Commissioner Peter Pitts to its Board…
This is a routine board expansion with a regulatory-savvy director. The key catalyst to watch is the company's ability to secure funding for the Phase 3b ENDURANCE trial, which is explicitly…
- BEARISH 8-KMay 15, 2026
BrainStorm Cell Therapeutics reported Q1 2026 results with a net loss of $2.1M ($0.19 per share)…
The company has essentially no cash runway — $15K unrestricted cash against $11.8M in current liabilities. The Phase 3b trial start is contingent on financing that has not been secured. Watch for a…
- BULLISH 8-KMar 31, 2026
BrainStorm Cell Therapeutics reported a narrower-than-expected net loss for full-year 2025, with…
The EPS beat and post-period financing reduce near-term dilution risk and support continued development of NurOwn. Traders should monitor enrollment progress in the Phase 3b trial and any FDA…
All BCLI filing & press-release reports (4)
- EFFECT reportJun 3, 2026
- 8-K reportMay 28, 2026
- 8-K reportMay 15, 2026
- 8-K reportMar 31, 2026